David Kirn, 4D Molecular Therapeutics CEO

4D Mol­e­c­u­lar paus­es en­roll­ment in Fab­ry tri­als af­ter kid­ney prob­lems in three pa­tients

4D Mol­e­c­u­lar Ther­a­peu­tics said it has stopped en­rolling pa­tients in its two clin­i­cal tri­als of a gene ther­a­py be­ing in­ves­ti­gat­ed for Fab­ry dis­ease.

The biotech will wait un­til the sec­ond half to eval­u­ate 12-month clin­i­cal da­ta on the six pa­tients en­rolled on 4D-310. The two tri­als, one in the US and the oth­er in Tai­wan and Aus­tralia, were each es­ti­mat­ed to en­roll 18 adults with the dis­ease, in which the body lacks the en­zymes need­ed to break down fats. For those with the in­her­it­ed lipid stor­age dis­or­der, fats build up in blood ves­sels and tis­sue, which leads to dif­fi­cul­ties in the kid­neys, heart and ner­vous sys­tem.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.